Erik Penser Bank publishes analysis of Initiator Pharma
Initiator Pharma A/S, a clinical-stage biotech company, announced that Erik Penser Bank has made an analysis of the company. Erik Penser Bank’s valuation indicates a justified value of SEK 11-12 (WACC 16%). The valuation rests on the company's two clinical projects, with IPED2015 and IP2018. For the full analysis, please follow this link .Initiator Pharma currently has an ongoing exercise period for the warrants of series TO 2. The last day to exercise the warrants is on Tuesday, the 15[th] of December 2020. For more information about the